相关实验视频
Updated: Jun 14, 2025
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
822
蒂罗菲班诱导的扩散膜出血.
Bryan Sebastian1, Vijayan Ganesan2, Placid Sebastian1
1Cardiology, Aster MIMS Hospital, Kannur, Kerala, India.
BMJ case reports
|August 29, 2024
概括
用于治疗心脏病发作的药物 - - 铁洛菲班的一种罕见并发症是扩散膜出血 (DAH). 迅速停止药物治疗和提供支持性护理导致了患者的康复.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- ST升高心肌梗塞 (STEMI) 是一个关键的心脏事件,需要紧急干预.
- 蒂罗菲班是一种抗血小板药物,用于治疗急性冠状动脉综合征,特别是患有广泛血栓的冠状动脉综合征.
- 扩散膜出血 (DAH) 是一种严重的,经常被忽视的肺部并发症.
研究的目的:
- 在STEMI患者中报告一种二次于tirofiban的DAH罕见病例.
- 要突出临床表现,诊断方面的挑战,以及提洛菲班诱导的DAH的管理.
- 强调早期识别和干预这种危及生命的疾病的重要性.
主要方法:
- 一个中年男性患者的病例报告显示,他患有劣质的STEMI.
- 主要皮肤穿透冠状动脉干预与tirofiban广泛的血栓.
- 临床监测,胸部X射线和高分辨率CT扫描用于呼吸系统症状.
- 通过支持性护理进行管理,包括内药物,非侵入性通风和furosemide.
主要成果:
- 患者在开始服用蒂罗菲班后不久就出现了急性呼吸不良,血栓塞和低血压.
- 高分辨率CT证实了DAH具有特有的"疯狂路面"外观.
- 停止提罗菲班和抗凝剂,以及支持性治疗,导致肺不透明的完全解决.
- 患者在两个月的随访后完全康复.
结论:
- 蒂罗菲班可以诱导DAH,这是一个罕见但严重的不良事件.
- 早期诊断和停止侵扰剂对于管理罗非班诱导的DAH至关重要.
- 涉及心脏病学和肺病学的多学科管理对于有利的结果至关重要.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:24Disorders of Hemostasis
754
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
754
01:16Clot Retraction and Fibrinolysis
4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K